AGuIX nanoparticles enhance ionizing radiation-induced ferroptosis on tumor cells by targeting the NRF2-GPX4 signaling pathway.


Journal

Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208

Informations de publication

Date de publication:
14 Oct 2022
Historique:
received: 09 06 2022
accepted: 25 09 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 19 10 2022
Statut: epublish

Résumé

In the frame of radiotherapy treatment of cancer, radioresistance remains a major issue that still needs solutions to be overcome. To effectively improve the radiosensitivity of tumors and reduce the damage of radiation to neighboring normal tissues, radiosensitizers have been given increasing attention in recent years. As nanoparticles based on the metal element gadolinium, AGuIX nanoparticles have been shown to increase the radiosensitivity of cancers. Although it is a rare nanomaterial that has entered preclinical trials, the unclear biological mechanism hinders its further clinical application. In this study, we demonstrated the effectiveness of AGuIX nanoparticles in the radiosensitization of triple-negative breast cancer. We found that AGuIX nanoparticles increased the level of DNA damage by compromising the homologous recombination repair pathway instead of the non-homologous end joining pathway. Moreover, the results showed that AGuIX nanoparticles induced apoptosis, but the degree of apoptosis ability was very low, which cannot fully explain their strong radiosensitizing effect. Ferroptosis, the other mode of cell death, was also discovered to play a significant role in radiation sensitization, and AGuIX nanoparticles may regulate the anti-ferroptosis system by inhibiting the NRF2-GSH-GPX4 signaling pathway.

Identifiants

pubmed: 36242003
doi: 10.1186/s12951-022-01654-9
pii: 10.1186/s12951-022-01654-9
pmc: PMC9569109
doi:

Substances chimiques

AGuIX 0
NF-E2-Related Factor 2 0
Radiation-Sensitizing Agents 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

449

Subventions

Organisme : National Natural Science Foundation of China
ID : 81972976
Organisme : National Natural Science Foundation of China
ID : 31900889
Organisme : National Natural Science Foundation of China
ID : 82072331
Organisme : National Natural Science Foundation of China
ID : 32071241
Organisme : National Natural Science Foundation of China
ID : 31900891
Organisme : National Natural Science Foundation of China
ID : 82103837
Organisme : National Natural Science Foundation of China
ID : 31971168
Organisme : National Natural Science Foundation of China
ID : 32171239
Organisme : Natural Science Foundation of Tianjin
ID : 20JCQNJC00340
Organisme : Fundamental Research Funds for the Central Universities
ID : 3332021066

Informations de copyright

© 2022. The Author(s).

Références

Adv Mater. 2019 Dec;31(51):e1904197
pubmed: 31595562
J Biol Chem. 2007 Nov 2;282(44):32243-55
pubmed: 17715134
Nano Lett. 2017 Mar 8;17(3):1733-1740
pubmed: 28145723
Science. 2004 Apr 2;304(5667):93-6
pubmed: 15064416
Nanoscale. 2022 Aug 11;14(31):11429-11442
pubmed: 35904053
Chemistry. 2013 May 3;19(19):6122-36
pubmed: 23512788
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Biomaterials. 2013 Jan;34(1):181-95
pubmed: 23046756
Theranostics. 2016 Jan 20;6(3):418-27
pubmed: 26909115
Breast Cancer Res. 2012 Jan 06;14(1):R5
pubmed: 22225950
Cancers (Basel). 2020 Feb 25;12(3):
pubmed: 32106627
Cancer Radiother. 2015 Oct;19(6-7):508-14
pubmed: 26343033
Adv Sci (Weinh). 2020 Oct 28;7(24):2003584
pubmed: 33344143
Biomaterials. 2017 Mar;120:155-184
pubmed: 28063356
Science. 2007 May 25;316(5828):1160-6
pubmed: 17525332
Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123
pubmed: 32729622
Cancer Res. 2009 Jan 15;69(2):383-92
pubmed: 19147546
Front Bioeng Biotechnol. 2019 Nov 27;7:368
pubmed: 31828068
Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88
pubmed: 34508254
Nat Chem Biol. 2017 Jan;13(1):91-98
pubmed: 27842070
Cell Res. 2020 Feb;30(2):146-162
pubmed: 31949285
Oncotarget. 2017 Jul 11;8(28):46652-46662
pubmed: 28445140
Nat Genet. 2001 Mar;27(3):247-54
pubmed: 11242102
JAMA Oncol. 2016 Aug 1;2(8):1075-82
pubmed: 27243924
Sci Adv. 2020 Jul 15;6(29):eaay5279
pubmed: 32832613
Subcell Biochem. 2002;36:171-86
pubmed: 12037980
Theranostics. 2015 Jun 11;5(9):1030-44
pubmed: 26155318
J Biol Chem. 1995 Aug 11;270(32):18738-41
pubmed: 7543896
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
ACS Appl Mater Interfaces. 2020 Dec 23;12(51):56874-56885
pubmed: 33326207
Nature. 2000 Nov 23;408(6811):429-32
pubmed: 11100717
J Nanobiotechnology. 2016 Jul 28;14(1):63
pubmed: 27464501
Sci Rep. 2016 Sep 23;6:34040
pubmed: 27658637
Mol Neurobiol. 2020 Nov;57(11):4628-4641
pubmed: 32770451
Sci Adv. 2021 Sep 24;7(39):eabj8833
pubmed: 34550744
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
Nat Rev Mol Cell Biol. 2013 Apr;14(4):197-210
pubmed: 23847781
J Clin Oncol. 2011 Jul 20;29(21):2852-8
pubmed: 21670451
Expert Opin Pharmacother. 2015 May;16(7):983-98
pubmed: 25881743
Genome Integr. 2012 Nov 27;3(1):9
pubmed: 23181949
Nat Commun. 2017 Jun 12;8:15760
pubmed: 28604675
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Cell. 1997 Oct 31;91(3):325-34
pubmed: 9363941
Cancer Radiother. 2019 Dec;23(8):917-921
pubmed: 31540838
Nat Rev Clin Oncol. 2012 Dec;9(12):688-99
pubmed: 23165124
Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12
pubmed: 23012306
Cancer Nanotechnol. 2015;6(1):4
pubmed: 26345984
Trends Pharmacol Sci. 2018 Jan;39(1):24-48
pubmed: 29224916
Nat Biotechnol. 2007 Oct;25(10):1165-70
pubmed: 17891134
Redox Biol. 2019 May;23:101107
pubmed: 30692038
Nat Rev Mol Cell Biol. 2008 Mar;9(3):231-41
pubmed: 18073771
Br J Radiol. 2014 Sep;87(1041):20140134
pubmed: 24990037
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970

Auteurs

Hao Sun (H)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Hui Cai (H)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Chang Xu (C)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Hezheng Zhai (H)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.
School of Precision Instruments and OPTO-Electronics Engineering, Tianjin University, Tianjin, 300072, China.

François Lux (F)

Institute Light and Mater, UMR5306, Lyon1 University-CNRS, Lyon University, 69100, Villeurbanne, France.
Institut Universitaire de France (IUF), 75231, Paris, France.

Yi Xie (Y)

Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730000, China.

Li Feng (L)

Department of Medical Ultrasound, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medical Imaging, Jinan, 250014, China.

Liqing Du (L)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Yang Liu (Y)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Xiaohui Sun (X)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Qin Wang (Q)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Huijuan Song (H)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Ningning He (N)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Manman Zhang (M)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Kaihua Ji (K)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Jinhan Wang (J)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Yeqing Gu (Y)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China.

Géraldine Leduc (G)

NH TherAguix S.A.S, 29 chemin du Vieux Chêne, 38240, Meylan, France.

Tristan Doussineau (T)

NH TherAguix S.A.S, 29 chemin du Vieux Chêne, 38240, Meylan, France.

Yan Wang (Y)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China. wangyan@irm-cams.ac.cn.

Qiang Liu (Q)

Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300192, China. liuqiang@irm-cams.ac.cn.

Olivier Tillement (O)

Institute Light and Mater, UMR5306, Lyon1 University-CNRS, Lyon University, 69100, Villeurbanne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH